Delving into the Latest Updates on Glaxosmithkline Vaccines Srl with Synapse

概览

疾病领域	数量

感染	1
神经系统疾病	1

排名前五的药物类型	数量

灭活疫苗	1
预防性疫苗	1

关联

1

项与 Glaxosmithkline Vaccines Srl 相关的药物

Meningococcal group B vaccine(GlaxoSmithKline Biologicals SA)

B群脑膜炎球菌疫苗(Novartis Pharma AG)

靶点-

作用机制

免疫刺激剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

欧盟 [+3]

首次获批日期2013-01-13

100 项与 Glaxosmithkline Vaccines Srl 相关的临床结果

登录后查看更多信息

0 项与 Glaxosmithkline Vaccines Srl 相关的专利（医药）

登录后查看更多信息

7

项与 Glaxosmithkline Vaccines Srl 相关的文献（医药）

A Re-assessment of 4CMenB Vaccine Effectiveness Against Serogroup B Invasive Meningococcal Disease in England based on an Incidence Model

作者: Vadivelu, Kumaran ; Abbing-Karahagopian, Victoria ; Medini, Duccio ; Rappuoli, Rino ; Argante, Lorenzo

AbstractBackground: The four-component serogroup B meningococcal 4CMenB vaccine (Bexsero, GSK) has been routinely given to all infants in the United Kingdom at 2, 4 and 12 months of age since September 2015. After three years, Public Health England (PHE) reported a 75% [95% confidence interval: 64%; 81%] reduction in the incidence of serogroup B invasive meningococcal disease (IMD) in age groups eligible to be fully vaccinated. In contrast, vaccine effectiveness (VE) evaluated in the same immunization program applying the screening method was not statistically significant. We re-analyzed the data using an incidence model and obtained more precise VE estimates. Methods: Aggregate data stratified by age, year and doses received were provided by PHE: serogroup B IMD case counts for the entire population of England (years 2011-2018) and 4CMenB vaccine uptake in infants. We combined uptake with national population estimates to obtain counts of vaccinated and unvaccinated person-time by age and time. We re-estimated VE comparing incidence rates in vaccinated and non-vaccinated using a Bayesian Poisson model for case counts with person-time data as an offset. The model was adjusted for age, time and number of doses received. Results: The incidence model showed that cases decreased until 2013-2014, followed by an increasing trend that continued in the non-vaccinated population during the immunization program. VE in fully vaccinated (three doses) was 80.1% [95% Bayesian credible interval (BCI): 70.3%; 86.7%]. After a single dose, VE was 33.5% [12.4%; 49.7%]95%BCI, and, after two doses, 78.7% [71.5%; 84.5%]95%BCI. We estimated that vaccination has averted 312 cases [252; 368]95%BCI between 2015 and 2018. VE was in line with the previously reported incidence reduction. Conclusions: Our estimates of VE had higher precision than previous estimates based on the screening method, that were not statistically significant. When disease incidence is low and vaccine uptake is high, the screening method applied to cases exclusively from the population eligible to vaccination may not be enough precise and produce misleading point-estimates. Precise and accurate VE estimates are fundamental for informing public health decision making. VE assessment can be enhanced using models that leverage data on subjects not eligible for vaccination.

Histological Study of Sheep Skin Transformation in the Course of Parchment Manufacturing Process

作者: Fourneau, Marc ; Deparis, Olivier ; Vlaender, Daniel Van ; Collins, Matthew J. ; Canon, Caroline ; Fiddyment, Sarah ; Poumay, Yves

AbstractWe report a simple histological study on skin biopsies from young domestic sheep following each step in transformation from skin to parchment production. Histological analyses were conducted; before and after lime treatment, hair removal, and stretching. Sections were fixed and stained using a variety of histological stains to identify the presence of different molecular classes and the fibrous proteins, collagen and elastin. The results reveal surprisingly few histological changes in most steps in the production process. However, very visible changes in the supramolecular ordering of skin macromolecules (elastin, collagen) occur during the final stage of parchment production when stretched on the frame. Collagen fibres and hair follicles were all strongly re-oriented in the direction of strain. Surprisingly, despite the thinness of the lambskin and the exhaustive treatment in lime, not all fats were saponified and even in the final product Oil Red O stained fat bodies were detectable on the hair side of the skin.

Influenza-associated respiratory illness among five cohorts of pregnant women and their young infants (0-6 months), Bangladesh, 2013-2017

作者: Howlader, Md. ; Dawood, Fatimah ; Rahman, Mohammed ; Sturm-Ramirez, Katherine ; Iuliano, Angela ; Bhuiyan, Mejbah ; Akhtar, Zubair ; Ghosh, Probir ; Chowdury, Fahmida

Pregnant women with their infants are considered at higher risk for influenza-associated complications, and the WHO recommends influenza vaccination during pregnancy to protect them, including their infants (0-6 months). There are limited data on the influenza burden among pregnant women and their infants (0-6 months), and there is no routine influenza vaccination in Bangladesh. Five annual cohorts (2013-2017) of pregnant women were enrolled from 8 sub-districts of Bangladesh before the influenza season (May-September); contacted weekly to identify new onset of influenza-like illness (ILI) (subjective or measured fever and cough) and acute respiratory illness (ARI) (at least two of: cough, rhinorrhea, or difficulty breathing) among their infants from birth to 6 months of age. We collected nasopharyngeal swabs from ILI and ARI cases, tested by rRT-PCR for influenza virus (including types and subtypes) and estimated influenza incidence (95% CI) /10,000 pregnancy-months or infant-months, respectively. We enrolled 9,020 pregnant women, followed for 26,709 pregnancy-months and detected 1,241 ILI episodes. We also followed 8,963 infants for 51,518 infant-months and identified 5,116 ARI episodes. Influenza positivity was 23% for ILI and 3% for ARI cases. The overall incidence (2013-2017) of influenza among pregnant women was 158.5/10,000 pregnancy-months (95% CI: 141.4-177.6), and that among infants was 21.9/10,000 infant-months (95% CI: 18.2-26.5). Although the data was collected more than five years ago, as the only baseline data, our findings illustrate evidence of influenza burden among pregnant women and infants (0-6 months) which may support preventive policy decisions in Bangladesh.

100 项与 Glaxosmithkline Vaccines Srl 相关的药物交易

登录后查看更多信息

100 项与 Glaxosmithkline Vaccines Srl 相关的转化医学

登录后查看更多信息